References
Clamp, A. R., James, E. C., McNeish,
I. A., Dean, A., Kim, J.-W., O’Donnell, D. M., . . . Ledermann, J. A.
(2019). Weekly dose-dense chemotherapy in first-line epithelial ovarian,
fallopian tube, or primary peritoneal carcinoma treatment (ICON8):
primary progression free survival analysis results from a GCIG phase 3
randomised controlled trial. The Lancet, 394 (10214), 2084-2095.
doi:10.1016/s0140-6736(19)32259-7
De Bono, J. S., Oudard, S., Ozguroglu,
M., Hansen, S., Machiels, J.-P., Kocak, I., . . . Sartor, A. O. (2010).
Prednisone plus cabazitaxel or mitoxantrone for metastatic
castration-resistant prostate cancer progressing after docetaxel
treatment: a randomised open-label trial. The Lancet, 376 (9747),
1147-1154. doi:10.1016/s0140-6736(10)61389-x
Ghersi, D., Willson, M. L., Chan, M.
M. K., Simes, J., Donoghue, E., & Wilcken, N. (2015). Taxane-containing
regimens for metastatic breast cancer. Cochrane Database Syst Rev,
2015 (6), CD003366-CD003366. doi:10.1002/14651858.CD003366.pub3
Gosain, R., Abdou, Y., Singh, A.,
Rana, N., Puzanov, I., & Ernstoff, M. S. (2020). COVID-19 and Cancer: a
Comprehensive Review. Curr Oncol Rep, 22 (5), 53.
doi:10.1007/s11912-020-00934-7
Helgason, H. H., Kruijtzer, C. M. F.,
Huitema, A. D. R., Marcus, S. G., Ten Bokkel Huinink, W. W., Schot, M.
E., . . . Schellens, J. H. M. (2006). Phase II and pharmacological study
of oral paclitaxel (Paxoral) plus ciclosporin in
anthracycline-pretreated metastatic breast cancer. 95 (7),
794-800. doi:10.1038/sj.bjc.6603332
Jackson, C. G. C. A., Bayston, K. F.,
McLaren, B. R., Bremer, L., Eden, K., Kwan, M.-F. R., . . . Hung, T.
(2016). An open label, randomised cross-over bioavailability study of
oral paclitaxel (oraxol) compared to intravenous paclitaxel 80mg/m2.Journal of Clinical Oncology, 34 (15_suppl), 2569-2569.
doi:10.1200/JCO.2016.34.15_suppl.2569
Jibodh, R. A., Lagas, J. S., Nuijen,
B., Beijnen, J. H., & Schellens, J. H. (2013). Taxanes: old drugs, new
oral formulations. Eur J Pharmacol, 717 (1-3), 40-46.
doi:10.1016/j.ejphar.2013.02.058
Joerger, M. (2016). Treatment regimens
of classical and newer taxanes. Cancer Chemother Pharmacol,
77 (2), 221-233. doi:10.1007/s00280-015-2893-6
Kartner, N., Riordan, J. R., & Ling,
V. (1983). Cell surface P-glycoprotein associated with multidrug
resistance in mammalian cell lines. Science, 221 (4617),
1285-1288. doi:10.1126/science.6137059
Kim, T.-E., Gu, N., Yoon, S. H., Cho,
J.-Y., Park, K.-M., Shin, S.-G., . . . Yu, K.-S. (2012). Tolerability
and Pharmacokinetics of a New P-Glycoprotein Inhibitor, HM30181, in
Healthy Korean Male Volunteers: Single- and Multiple-Dose Randomized,
Placebo-Controlled Studies. 34 (2), 482-494.
doi:10.1016/j.clinthera.2012.01.003
Lee, H., Park, S., Kang, J. E., Lee,
H. M., Kim, S. A., & Rhie, S. J. (2020). Efficacy and safety of
nanoparticle-albumin-bound paclitaxel compared with solvent-based
taxanes for metastatic breast cancer: A meta-analysis. Scientific
Reports, 10 (1). doi:10.1038/s41598-019-57380-0
Lee, H. J., Heo, D.-S., Cho, J.-Y.,
Han, S.-W., Chang, H.-J., Yi, H.-G., . . . Bang, Y.-J. (2014). A Phase I
Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor,
HM30181A, in Patients with Advanced Solid Cancer. 46 (3), 234-242.
doi:10.4143/crt.2014.46.3.234
Lee, K. W., Lee, K. H., Zang, D. Y.,
Park, Y. I., Shin, D. B., Kim, J. W., . . . Bang, Y. J. (2015). Phase
I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients
With Metastatic or Recurrent Gastric Cancer. 20 (8), 896-897.
doi:10.1634/theoncologist.2015-0202
Lu, Z., Zhang, X., Liu, W., Liu, T.,
Hu, B., Li, W., . . . Shen, L. (2018). A multicenter, randomized trial
comparing efficacy and safety of paclitaxel/capecitabine and
cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer,
21 (5), 782-791. doi:10.1007/s10120-018-0809-y
Malingré, M. M., Terwogt, J. M.,
Beijnen, J. H., Rosing, H., Koopman, F. J., van Tellingen, O., . . .
Schellens, J. H. (2000). Phase I and pharmacokinetic study of oral
paclitaxel. J Clin Oncol, 18 (12), 2468-2475.
doi:10.1200/jco.2000.18.12.2468
Masters, G. A., Temin, S., Azzoli, C.
G., Giaccone, G., Baker, S., Brahmer, J. R., . . . Johnson, D. H.
(2015). Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer:
American Society of Clinical Oncology Clinical Practice Guideline
Update. Journal of Clinical Oncology, 33 (30), 3488-3515.
doi:10.1200/jco.2015.62.1342
Paek, I. B., Ji, H. Y., Kim, M. S.,
Lee, G., & Lee, H. S. (2006). Metabolism of a new P-glycoprotein
inhibitor HM-30181 in rats using liquid chromatography/electrospray mass
spectrometry. 20 (9), 1457-1462. doi:10.1002/rcm.2468
Paek, I. B., Ji, H. Y., Kim, M. S.,
Lee, G. S., & Lee, H. S. (2006). Simultaneous determination of
paclitaxel and a new P-glycoprotein inhibitor HM-30181 in rat plasma by
liquid chromatography with tandem mass spectrometry. 29 (5),
628-634. doi:10.1002/jssc.200500368
Rowinsky, E. K. (1997). Paclitaxel
pharmacology and other tumor types. Semin Oncol, 24 (6 Suppl 19),
S19-11-s19-12.
Schellens, J. H. M., Malingré, M. M.,
Kruijtzer, C. M. F., Bardelmeijer, H. A., Van Tellingen, O., Schinkel,
A. H., & Beijnen, J. H. (2000). Modulation of oral bioavailability of
anticancer drugs: from mouse to man. 12 (2), 103-110.
doi:10.1016/s0928-0987(00)00153-6
Schrag, D., Hershman, D. L., &
Basch, E. (2020). Oncology Practice During the COVID-19 Pandemic.JAMA, 323 (20), 2005-2006. doi:10.1001/jama.2020.6236
Umanzor, G., Cutler, D. L., Barrios,
F. J., Vassallo, R. H., Chivalan, M. A., Bejarano, S. A., . . . Kwan, R.
M. F. (2020). Abstract GS6-01: Oral paclitaxel with encequidar: The
first orally administered paclitaxel shown to be superior to IV
paclitaxel on confirmed response and survival with less neuropathy: A
phase III clinical study in metastatic breast cancer. Cancer
Research, 80 (4 Supplement), GS6-01.
doi:10.1158/1538-7445.SABCS19-GS6-01
van Asperen, J., van Tellingen, O.,
van der Valk, M. A., Rozenhart, M., & Beijnen, J. H. (1998). Enhanced
oral absorption and decreased elimination of paclitaxel in mice
cotreated with cyclosporin A. Clin Cancer Res, 4 (10), 2293-2297.
Walsh, V., & Goodman, J. (2002). The
billion dollar molecule: Taxol in historical and theoretical
perspective. Clio Med, 66 , 245-267.
doi:10.1163/9789004333499_013
Wani, M. C., Taylor, H. L., Wall, M.
E., Coggon, P., & McPhail, A. T. (1971). Plant antitumor agents. VI.
Isolation and structure of taxol, a novel antileukemic and antitumor
agent from Taxus brevifolia. Journal of the American Chemical
Society, 93 (9), 2325-2327. doi:10.1021/ja00738a045